GlobalReach Health

December 13, 2022

Biosimilar Idacio receives FDA Approval

December 13, 2022 – Idacio (adalimumab-aacf), a tumor necrosis factor (TNF) blocker biosimilar to Humira, has been approved by the FDA for the treatment of rheumatoid arthritis